About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on brain disorders. The Company has a broad clinical and preclinical pipeline in indications including addiction, anxiety, fatigue, narcolepsy, glioblastoma* and neurodevelopmental disorders [*orphan indication].

The Company's strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid-size to large pharma for larger trials and commercialisation. It also has a number of industry partnerships with companies, including Stalicla SA, in neurodevelopmental disorders.  The Company has sourced know how for programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major universities and hospitals such as the University of Manchester, La Sapienza (Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College London and the University of Michigan.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is quoted on AIM in London and trades under the ticker symbol TCF. 

Dr Huw Jones, Executive Director

Chief Executive Officer

Huw has over 30 years’ experience of leadership roles in public and private R&D-based companies within the biotechnology and pharmaceutical sector, with a particular focus on preclinical and clinical drug development, dilutive and non-dilutive financing and business development. Most recently he was a Non-executive Director of Ixaka Ltd and Chairman of Chronos Therapeutics Ltd. Huw is a non-executive Director of biotech industry body OBN. Huw holds a PhD in pharmacology from the University of Birmingham, UK.

Dr Helen Kuhlman

Chief Business Officer

Helen has over 20 years’ experience in life sciences beginning her career as a research scientist at Cambridge Antibody Technology and Domantis, before transitioning into strategy and business development roles. She has been an active proponent of the UK biotech innovation ecosystem, leading the creation and delivery of the £180m Biomedical Catalyst competitive grant scheme, whilst at Innovate UK. In addition to her role in TheraCryf she is an Operating Advisor with SymBiosis Capital Management, a US based healthcare focused venture fund, and an independent board member of the University Commercialization Executive Board at the University of Bath. Helen holds a PhD in physiology and pharmacology from the University of Leicester, UK.

Toni Haenninen, Executive Director

Chief Financial Officer

Toni has over 20 years’ experience in business development and senior finance roles in both public and private companies, working in mature and emerging markets particularly in Europe and the USA where he has accomplished successful fundraises, transactions and fiscal management in the sector. He was previously CFO at Faron Pharmaceuticals Ltd., an AIM and Nasdaq First North listed clinical stage biopharmaceutical company based in the Finland and the US developing novel treatments for medical conditions with significant unmet needs. Toni has an MBA from the Helsinki School of Economics (currently Aalto University).

BASH is an acronym for Buy, Avoid, Sell and Hold a share in a company to be discussed during each panel.

Mark Simpson

Mark Simpson is a Value investor, writer and presenter. He focuses on finding sources of edge in the market and developing practical ways to overcome behavioural biases. His book Excellent Investing describes this approach and how investors of all types can generate higher and more consistent returns by developing a strategy that plays to their strengths and overcomes their weaknesses